5 results about "Normal pregnancy" patented technology

The invention relates to application of arachidonic acid (ARA) in preparation of a medicine for treating sleep disorder related spontaneous abortion. Peripheral blood lipid metabolism sequencing analysis finds that the ARA content in peripheral blood serum of a patient suffering from sleep disorder and repeated pregnancy loss is most obviously reduced compared with that of a patient suffering from normal sleep and normal pregnancy; an enzyme-linked immunosorbent assay test shows that the content of ARA in decidua stromal cells (DSCs) of a patient with sleep disorder and repeated pregnancy loss is remarkably reduced compared with that of a pregnant person with normal sleep; after the endometrial stromal cells (ESCs) are subjected to ARA treatment, the in-vitro decidualization level is increased; the ARA inhibitor can be used for inhibiting the in-vitro deciduation level of the ESCs; compared with a mouse with normal sleep, the content of ARA in peripheral blood and DSCs of a mouse with sleep disorder is remarkably reduced, decidua is poor, and the abortion rate is increased; supplementing ARA can improve decidua disorder and high abortion rate caused by sleep disorder. Therefore, a potential target and a new idea are provided for diagnosis and treatment of repeated pregnancy loss related to sleep disorder.

The present invention relates to an immune device for determining the presence or absence of pregnancy or abnormal pregnancy, and more specifically, to an immune device capable of recognizing both intact hCG and βcf hCG. R This immunological device contains a multi-linked anti-hCG monoclonal antibody, and can separately detect intact hCG and βcf hCG contained in the sample, including two detection lines and a control line.By quantifying the ratio of the color intensity of βcf hCG to the color intensity of intact hCG and βcf hCG (the distribution ratio of βcf hCG), it can accurately and quickly determine the number of weeks of pregnancy, normal pregnancy, ectopic pregnancy, and abnormal pregnancy including blighted oocytes.

The application discloses a serine nano-drug for treating preeclampsia by targeting placental oxidative stress, which can pass through the placental barrier by changing the particle size, thereby increasing the local concentration of serine in the placenta to achieve the purpose of relieving placental oxidative stress and treating preeclampsia. The placental barrier is the barrier between the placental villus tissue and the uterine blood sinus, and is an important basis for maintaining normal pregnancy. However, the placental barrier also hinders the entry of drugs into the placenta, affecting the treatment effect of drugs on placental diseases, such as preeclampsia, fetal intrauterine growth restriction and the like. The nano-drug is prepared by using nano-preparation technology to make raw drugs into particles with a nano scale, and has the advantage of penetrating through the body barrier. The amino acid involved in oxidative stress regulation, serine, is synthesized into nano-serine by using nano technology, so that serine can pass through the placental barrier by changing the particle size of nano-serine, thereby increasing the local concentration of serine in the placenta, and achieving the purpose of treating preeclampsia by reducing placental oxidative stress.

The invention provides an application of judiciyumab in preparation of a medicine for improving the living yield of a patient with recurrent abortion (RSA), and belongs to the field of biological medicine. The Jukoulikumab provided by the invention is a fully humanized monoclonal antibody, can inhibit inflammatory reaction generated by IL-17A activation on the basis of not influencing other immune functions of a body, and has high selectivity. When being applied to mice and RSA patients in the pregnancy period, the Jukoulikumab can improve the immune tolerance of a maternal-fetal interface, obviously improve the embryo survival rate of the RSA mice and the RSA patients, even can reach the same level as normal pregnancy, and does not find embryo or maternal abnormality, so that a new evidence is provided for the pregnant patients to use the Jukoulikumab, and the Jukoulikumab has a wide application prospect. And the safety and the effectiveness of treating the RSA by using the judiciyumab are powerfully proved.

The application discloses a biomarker for predicting unexplained recurrent spontaneous abortion and application thereof, and belongs to the technical field of molecular diagnosis and molecular biology. By comparing serum detection of 45 unexplained recurrent spontaneous abortion patients, it is found that the expression level of miR-142-3p in the serum of the unexplained recurrent spontaneous abortion patients is obviously higher than that of normal pregnant women. Compared with the normal pregnant women, the peripheral blood CD4 + CD25 + Treg cell level of the unexplained recurrent spontaneous abortion patients is significantly increased. By detecting the expression level of miR-142-3p, the unexplained recurrent spontaneous abortion patients can be pre-judged, so that the miR-142-3p can be used as an important index for clinically diagnosing and evaluating unexplained recurrent spontaneous abortion.